We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Vertex Pharmaceuticals
VRTX
$121B
| $161M | 0.37% |
572,030
-221,260
| -28% | -$59.2M |
|
52
S&P Global
SPGI
$121B
| $161M | 0.37% |
476,520
+36,700
| +8% | +$13.1M |
|
53
Philip Morris
PM
$297B
| $159M | 0.37% |
1,614,354
-4,000
| -0.2% | -$408K |
|
54
NextEra Energy
NEE
$181B
| $157M | 0.36% |
2,025,913
+207,000
| +11% | +$15.8M |
|
55
AT&T
T
$159B
| $156M | 0.36% |
7,455,739
-1,986,816
| -21% | -$39.6M |
|
56
McDonald's
MCD
$192B
| $156M | 0.36% |
632,152
-169,747
| -21% | -$41.8M |
|
57
Linde
LIN
$221B
| $151M | 0.35% |
524,135
-11,100
| -2% | -$3.47M |
|
58
Intel
INTC
$455B
| $150M | 0.34% |
4,008,485
-143,600
| -3% | -$6.21M |
|
59
Qualcomm
QCOM
$155B
| $145M | 0.33% |
1,138,921
-12,900
| -1% | -$1.75M |
|
60
United Parcel Service
UPS
$88.6B
| $140M | 0.32% |
764,900
+3,500
| +0.5% | +$638K |
|
61
Merck
MRK
$322B
| $138M | 0.32% |
1,513,376
+310,700
| +26% | +$27.5M |
|
62
Advanced Micro Devices
AMD
$776B
| $129M | 0.3% |
1,687,694
+5,600
| +0.3% | +$524K |
|
63
Arthur J. Gallagher & Co
AJG
$64.1B
| $129M | 0.29% |
788,803
-358,900
| -31% | -$59.6M |
|
64
Union Pacific
UNP
$174B
| $128M | 0.29% |
601,192
-95,900
| -14% | -$21.8M |
|
65
CVS Health
CVS
$133B
| $127M | 0.29% |
1,365,674
-4,900
| -0.4% | -$478K |
|
66
Goldman Sachs
GS
$300B
| $125M | 0.29% |
422,109
+64,100
| +18% | +$20M |
|
67
Lowe's Companies
LOW
$117B
| $125M | 0.29% |
713,505
-127,300
| -15% | -$24.5M |
|
68
Mondelez International
MDLZ
$79.5B
| $124M | 0.28% |
1,995,797
+546,100
| +38% | +$34.5M |
|
69
American Tower
AMT
$80.8B
| $124M | 0.28% |
484,005
+8,400
| +2% | +$2.11M |
|
70
Lam Research
LRCX
$367B
| $122M | 0.28% |
2,867,700
-917,000
| -24% | -$43.7M |
|
71
Elevance Health
ELV
$81.5B
| $121M | 0.28% |
251,093
-2,400
| -0.9% | -$1.19M |
|
|
TWTR
72
DELISTED
Twitter, Inc.
TWTR
| $120M | 0.28% |
3,221,482
+2,386,482
| +286% | +$102M |
|
73
Shell
SHEL
$254B
| $119M | 0.27% |
2,275,000
-385,000
| -14% | -$21.6M |
|
74
Texas Instruments
TXN
$252B
| $118M | 0.27% |
769,444
+126,000
| +20% | +$21.2M |
|
75
Nike
NKE
$61.9B
| $116M | 0.27% |
1,134,361
+63,600
| +6% | +$7.52M |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.